Cargando…
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial
BACKGROUND: Irritable bowel syndrome (IBS) is reported by one in ten of the population accounting for up to 40% of new referrals to gastroenterology outpatients. Patients characteristically have abdominal discomfort and disturbed bowel habit. Diarrhoea-predominant IBS is characterised by frequent lo...
Autores principales: | Leighton, Matthew P, Lam, Ching, Mehta, Samir, Spiller, Robin C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551830/ https://www.ncbi.nlm.nih.gov/pubmed/23302220 http://dx.doi.org/10.1186/1745-6215-14-10 |
Ejemplares similares
-
A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D)
por: Lam, Ching, et al.
Publicado: (2016) -
A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
por: Garsed, Klara, et al.
Publicado: (2014) -
Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine
por: Jalanka, Jonna, et al.
Publicado: (2021) -
Randomised controlled trial of mesalazine in IBS
por: Barbara, Giovanni, et al.
Publicado: (2016) -
Impact of symptom severity in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D): results from two separate surveys of HCPs and patients with IBS-D
por: Emmanuel, Anton, et al.
Publicado: (2020)